A Randomized, Double-Blind, Multiple Dose, 3-way Crossover, Exploratory Study to Assess the Pharmacodynamic Effects of SAGE-217 Capsules in Healthy Adults Using a 5-hour Phase Advance Model of Insomnia

Trial Profile

A Randomized, Double-Blind, Multiple Dose, 3-way Crossover, Exploratory Study to Assess the Pharmacodynamic Effects of SAGE-217 Capsules in Healthy Adults Using a 5-hour Phase Advance Model of Insomnia

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 08 Jan 2018

At a glance

  • Drugs SAGE 217 (Primary)
  • Indications Dyskinesias; Essential tremor; Major depressive disorder; Parkinson's disease; Postnatal depression; Seizures
  • Focus Pharmacodynamics
  • Sponsors Sage Therapeutics
  • Most Recent Events

    • 08 Jan 2018 According to a Sage Therapeutics media release, results from this trial are expected in 1Q 2018.
    • 20 Dec 2017 Status changed from recruiting to active, no longer recruiting.
    • 18 Sep 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top